A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
Authors
Keywords
Pancreatic cancer, Oncolytic virus, HF10, EUS-guidance
Journal
BMC CANCER
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-05-25
DOI
10.1186/s12885-018-4453-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis
- (2017) Junji Furuse et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret A. Tempero et al. Journal of the National Comprehensive Cancer Network
- Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
- (2017) Ibrahim Ragab Eissa et al. Frontiers in Oncology
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions
- (2016) Sten Myrehaug et al. Expert Review of Anticancer Therapy
- Phase 1 dose-escalation clinical trial of EUS-guided injection of HF10 for unresectable locally advanced pancreatic cancer
- (2016) Yoshiki Hirooka et al. PANCREATOLOGY
- Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
- (2014) O. Katopodis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- An oncolytic adenovirus defective in pRb-binding (dl922–947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine
- (2011) M Bhattacharyya et al. CANCER GENE THERAPY
- The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models
- (2011) G Cherubini et al. GENE THERAPY
- Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer
- (2011) Lotta Kangasniemi et al. INTERNATIONAL JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer
- (2010) A Nakao et al. CANCER GENE THERAPY
- Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer
- (2010) Manabu Onimaru et al. CANCER LETTERS
- Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
- (2010) Takuji Okusaka et al. CANCER SCIENCE
- Oncolytic Adenoviral Mutants with E1B19K Gene Deletions Enhance Gemcitabine-induced Apoptosis in Pancreatic Carcinoma Cells and Anti-Tumor Efficacy In vivo
- (2009) S. Leitner et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started